CLS products for MR-guided laser ablation evaluated at University of Texas Medical Branch
Clinical Laserthermia Systems (CLS) (publ), announces that three patients, diagnosed with early stage prostate tumor disease, have received treatment at The Department of Radiology at University of Texas Medical Branch (UTMB). The purpose of these treatments was to evaluate TRANBERG® sterile single-use products for MR-guided laser ablation. The procedure was carried out according to plan and Dr. Eric Walser, interventional radiologist and responsible for the evaluation, was pleased with the performance of the products in an MR environment. The expected high precision during the treatment was achieved.
In August 2016 CLS and UTMB signed a Letter of Intent, aiming at a collaborative project intended to lead to routine treatment of cancer patients using TRANBERG® products for MR-guided laser ablation. The initial phase of the collaboration involves evaluation of CLS’ sterile single-use products, including laser applicators and introducers optimized for MR-guided treatments.
“These first three treatments with MR-guided laser ablation in the USA, costitute a very important mile stone for CLS, said Dan Mogren, Chief Commercial Officer at CLS. Over all I am very pleased with our products’ performance, but I can also see room for certain improvement, when it comes to increase the robustness and thereby make the product easier to manage, meaning shorter treatment time. The cooperation with Dr. Eric Walser and his experienced team at UTMB provides us with valuable information, supporting us in reaching our joint objective – better products and more treatment alternatives for cancer patients”, said Dan Mogren.
Of the three patients two were diagnosed with prostate cancer and one was diagnosed with BPH (benign prostatahyperplasi).
In its capacity as a center of health science and medical education, UTMB belongs to an extensive network of hospitals in the United States. More about University of Texas Medical Branch: www.utmb.edu
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person named below arranged for the release of this information on 11 May 2017.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: firstname.lastname@example.org
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s websites: www.clinicallaser.se